Civitas Therapeutics Appoints Timothy S. Nelson As Chairman Of The Board Of Directors
Published: Jan 08, 2014
Civitas Therapeutics, Inc., a biopharmaceutical company with a lead program in Parkinson’s disease that utilizes the proprietary ARCUS(TM) respiratory delivery platform, today announced the appointment of Timothy S. Nelson as Chairman of the Board of Directors. Civitas also announced today that it has completed enrollment in its ongoing Phase 2b clinical study for its lead compound CVT-301, with data expected by the end of the first quarter of this year.
Help employers find you! Check out all the jobs and post your resume.